Business Wire10.18.19
Surgical Innovation Associates (SIA), an early-stage medical device company, has announced the first use of its DuraSorb Monofilament Mesh by Chicago plastic surgeon Karol Gutowski, M.D., FACS, past president of the Illinois Society of Plastic Surgeons and clinical affiliate of both University of Chicago and University of Illinois. SIA developed the DuraSorb product line to improve clinical outcomes and reduce cost in plastic and reconstructive surgery; and the company recently partnered with opinion leaders in the field to initiate a limited U.S. commercial release.
“When selecting an absorbable mesh for soft tissue reinforcement, the combination of handling characteristics and duration of support must be considered,” said Gutowski, “The softness and drapeability of DuraSorb, in combination with its strength and absorption profile, makes it the obvious choice for a variety of surgical procedures in my practice.”
Much like an absorbable stitch, DuraSorb Monofilament Mesh is designed to integrate into the patient’s tissue in order to provide strong support during the critical initial phases of healing, and then slowly dissolve within one year, leaving the patient free from foreign material. The device brings cutting-edge polymer science and evidence-based engineering to a material that has been safely used in other surgical applications for decades.
“We’re thrilled to continue working with opinion-leaders like Dr. Gutowski to serve an unmet clinical need in soft tissue support,” said Alexei Mlodinow, CEO and co-founder of SIA. “The favorable results of the first cases in our limited launch of DuraSorb are tremendously rewarding for the innumerable people who helped bring this product to fruition.”
Peer-reviewed preclinical safety and performance data for DuraSorb was previously presented at the American College of Surgeons (ACS) Clinical Congress 2018, and Plastic Surgery Research Council (PSRC) 2019.
SIA is committed to bringing better outcomes to patients and lowering systemic costs through “for surgeon, by surgeon” innovation in reconstructive and cosmetic surgery. Founded in Chicago in 2016 through a licensing agreement between Northwestern University and affiliates of its Feinberg School of Medicine and Kellogg School of Management, SIA has since advanced its initial product from the idea stage through U.S. Food and Drug Administration clearance and into the operating room. The company now has multiple devices in development for a variety of plastic and reconstructive surgery applications.
“When selecting an absorbable mesh for soft tissue reinforcement, the combination of handling characteristics and duration of support must be considered,” said Gutowski, “The softness and drapeability of DuraSorb, in combination with its strength and absorption profile, makes it the obvious choice for a variety of surgical procedures in my practice.”
Much like an absorbable stitch, DuraSorb Monofilament Mesh is designed to integrate into the patient’s tissue in order to provide strong support during the critical initial phases of healing, and then slowly dissolve within one year, leaving the patient free from foreign material. The device brings cutting-edge polymer science and evidence-based engineering to a material that has been safely used in other surgical applications for decades.
“We’re thrilled to continue working with opinion-leaders like Dr. Gutowski to serve an unmet clinical need in soft tissue support,” said Alexei Mlodinow, CEO and co-founder of SIA. “The favorable results of the first cases in our limited launch of DuraSorb are tremendously rewarding for the innumerable people who helped bring this product to fruition.”
Peer-reviewed preclinical safety and performance data for DuraSorb was previously presented at the American College of Surgeons (ACS) Clinical Congress 2018, and Plastic Surgery Research Council (PSRC) 2019.
SIA is committed to bringing better outcomes to patients and lowering systemic costs through “for surgeon, by surgeon” innovation in reconstructive and cosmetic surgery. Founded in Chicago in 2016 through a licensing agreement between Northwestern University and affiliates of its Feinberg School of Medicine and Kellogg School of Management, SIA has since advanced its initial product from the idea stage through U.S. Food and Drug Administration clearance and into the operating room. The company now has multiple devices in development for a variety of plastic and reconstructive surgery applications.
